Sammer, M.* ; Zahnbrecher, E. ; Dobiasch, S. ; Girst, S.* ; Greubel, C.* ; Ilicic, K. ; Reindl, J.* ; Schwarz, B.* ; Siebenwirth, C.* ; Walsh, D.W.M.* ; Combs, S.E. ; Dollinger, G.* ; Schmid, T.E.
     
    
        
Proton pencil minibeam irradiation of an in-vivo mouse ear model spares healthy tissue dependent on beam size.
    
    
        
    
    
        
        PLoS ONE 14:e0224873 (2019)
    
    
    
      
      
	
	    Proton radiotherapy using minibeams of sub-millimeter dimensions reduces side effects in comparison to conventional proton therapy due to spatial fractionation. Since the proton minibeams widen with depth, the homogeneous irradiation of a tumor can be ensured by adjusting the beam distances to tumor size and depth to maintain tumor control as in conventional proton therapy. The inherent advantages of protons in comparison to photons like a limited range that prevents a dosage of distal tissues are maintained by proton minibeams and can even be exploited for interlacing from different beam directions. A first animal study was conducted to systematically investigate and quantify the tissue-sparing effects of proton pencil minibeams as a function of beam size and dose distributions, using beam widths between s = 95, 199, 306, 411, 561 and 883 mu m (standard deviation) at a defined center-to-center beam distance (ctc) of 1.8 mm. The average dose of 60 Gy was distributed in 4x4 minibeams using 20 MeV protons (LET similar to 2.7 keV/mu m). The induced radiation toxicities were measured by visible skin reactions and ear swelling for 90 days after irradiation. The largest applied beam size to ctc ratio (s/ctc = 0.49) is similar to a homogeneous irradiation and leads to a significant 3-fold ear thickness increase compared to the control group. Erythema and desquamation was also increased significantly 3-4 weeks after irradiation. With decreasing beam sizes and thus decreasing s/ctc, the maximum skin reactions are strongly reduced until no ear swelling or other visible skin reactions should occur for s/ctc < 0.032 (extrapolated from data). These results demonstrate that proton pencil minibeam radiotherapy has better tissue-sparing for smaller s/ctc, corresponding to larger peak-to-valley dose ratios PVDR, with the best effect for s/ctc < 0.032. However, even quite large s/ctc (e.g. s/ctc = 0.23 or 0.31, i.e. PVDR = 10 or 2.7) show less acute side effects than a homogeneous dose distribution. This suggests that proton minibeam therapy spares healthy tissue not only in the skin but even for dose distributions appearing in deeper layers close to the tumor enhancing its benefits for clinical proton therapy.
	
	
	    
	
       
      
	
	    
		Impact Factor
		Scopus SNIP
		Web of Science
Times Cited
		Scopus
Cited By
		Altmetric
		
	     
	    
	 
       
      
     
    
        Publication type
        Article: Journal article
    
 
    
        Document type
        Scientific Article
    
 
    
        Thesis type
        
    
 
    
        Editors
        
    
    
        Keywords
        Radiation-therapy; Radiotherapy; Optimization; Skin
    
 
    
        Keywords plus
        
    
 
    
    
        Language
        english
    
 
    
        Publication Year
        2019
    
 
    
        Prepublished in Year
        
    
 
    
        HGF-reported in Year
        2019
    
 
    
    
        ISSN (print) / ISBN
        1932-6203
    
 
    
        e-ISSN
        
    
 
    
        ISBN
        
    
    
        Book Volume Title
        
    
 
    
        Conference Title
        
    
 
	
        Conference Date
        
    
     
	
        Conference Location
        
    
 
	
        Proceedings Title
        
    
 
     
	
    
        Quellenangaben
        
	    Volume: 14,  
	    Issue: 11,  
	    Pages: ,  
	    Article Number: e0224873 
	    Supplement: ,  
	
    
 
    
        
            Series
            
        
 
        
            Publisher
            Public Library of Science (PLoS)
        
 
        
            Publishing Place
            Lawrence, Kan.
        
 
	
        
            Day of Oral Examination
            0000-00-00
        
 
        
            Advisor
            
        
 
        
            Referee
            
        
 
        
            Examiner
            
        
 
        
            Topic
            
        
 
	
        
            University
            
        
 
        
            University place
            
        
 
        
            Faculty
            
        
 
    
        
            Publication date
            0000-00-00
        
 
         
        
            Application date
            0000-00-00
        
 
        
            Patent owner
            
        
 
        
            Further owners
            
        
 
        
            Application country
            
        
 
        
            Patent priority
            
        
 
    
        Reviewing status
        Peer reviewed
    
 
     
    
        POF-Topic(s)
        30203 - Molecular Targets and Therapies
    
 
    
        Research field(s)
        Radiation Sciences
    
 
    
        PSP Element(s)
        G-501300-001
    
 
    
        Grants
        
    
 
    
        Copyright
        
    
 	
    
    
    
    
    
        Erfassungsdatum
        2019-12-02